Latest news

ESC 2016: Short-term DAPT is feasible with Nobori biodegradable polymer stent

The NIPPON (Nobori dual antiplatelet therapy as appropriate duration) study, presented in a hotline session at the ESC today, indicates that in patients undergoing...


What is required for TAVI to become the new gold standard?

Since its introduction into clinical practice, transcatheter aortic valve implantation (TAVI) has revolutionised the treatment of aortic stenosis and has entered international guideline recommendations.1,2...

TAVI durability: A rose by any other name is still a...

The data that Dvir presented at EuroPCR, as reported by Cardiovascular News, indicate that there is a significant increase in valve degeneration between five and seven years after a transcatheter aortic valve implantation (TAVI) device is implanted.


In this CTSNet video, filmed at the 2016 STS Annual Meeting (Phoenix, USA), Pieter Kappetein (Erasmus MC Thoraxcenter, Rotterdam, The Netherlands), Moritz Wyler von Ballmoos (Duke University Medical Center, Durham, USA), and Aurelio Chaux (Cedars-Sinai Medical Center, Los Angeles, USA) discuss the ethics...


James Blankenship

Alexandra Lansky

Corrado Tamburino